Bridging the Needs of Security and Development Teams, Veracode Unveils Next-Generation Software Security Platform
4.5.2022 15:12:00 EEST | Business Wire | Press release
Veracode, a leading global provider of application security testing (AST) solutions, today announced its Continuous Software Security Platform, which seamlessly embeds application security into the software development lifecycle (SDLC). The platform streamlines workflows by bringing together development and security teams to provide a broad understanding of risk, remediation guidance, and progress at every stage of the development process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005671/en/
Fig. 1 The Veracode Continuous Software Security Platform (Graphic: Business Wire)
According to Veracode’s latest research, there has been a 20x increase in average scan cadence over the past decade, with most applications tested three times per week, as opposed to three times per year a decade ago. The research also showed a 31 percent increase in organizations using multiple scan types over the last three years alone.
Today, leading organizations recognize the need to leverage multiple methods to assess their software and do so across all stages of the development lifecycle. Gartner® predicts that “by 2025, 70% of organizations will consolidate the number of vendors securing the lifecycle of cloud-native applications to a maximum of three vendors.” ¹ This suggests companies are already looking for a comprehensive platform that provides flexible policy management, a holistic assessment of software risk, and integrated remediation guidance, while simplifying the complexity of managing multiple solutions.
Pervasive but Not Invasive for Developers
With increased pressure to build and deploy software at breakneck speed, development teams require security checks to be seamlessly integrated into the tools where they work so they can find and fix vulnerabilities quickly. Meanwhile, security teams must meet increasingly stringent compliance standards defined by their boards and regulatory bodies. Veracode’s Continuous Software Security Platform is pervasive but not invasive because it provides a frictionless experience for developers by embedding vulnerability analysis with remediation guidance directly into the integrated development environment.
Brian Roche, Chief Product Officer at Veracode, said, “Other vendors in our space have incomplete or disjointed solutions that lack consistent reporting and analysis, leaving customers playing a game of ‘whack a mole’ across different tools. We have continued to evolve our platform to create a seamless and integrated experience for developers, as well as provide security teams with a holistic view of their software security posture from design, through development and deployment. We see this as a win for both development and security teams that will result in the delivery of software that is more secure.”
Veracode Continuous Software Security Platform
The Veracode Continuous Software Security Platform enables users to define and manage security policy, gain a comprehensive view of software security across their application portfolio, and leverage rich analytics to make informed plans, communicate metrics, comply with policy, and meet regulatory requirements. Powered by almost two decades of data, the platform enables organizations to detect, predict, manage, and, ultimately, mitigate their security risk. These intelligent capabilities empower companies to deliver secure code at the speed and scale expected in today’s world.
The new Veracode Continuous Software Security Platform release features several new capabilities including:
- Single-Pane-of-Glass Reporting: Security teams can now access unified reporting directly in the portal for Static Analysis, Dynamic Analysis, Software Composition Analysis, and Manual Penetration Testing. Administrators and developers now have a consolidated view into security risks, as well as flexible policy controls through stronger license management reports to address issues quickly.
- Self-Service Peer Benchmarking: With comprehensive data and anonymized insights across all platform users, customers now have direct access to reports on the portal, which enable them to easily benchmark their DevSecOps program results against others in their industry. Tapping into many years of data and learning, customers can see how their program metrics stack up and establish plans to address their risk.
- Software Bill of Materials (SBOM): Security teams can now generate and export SBOMs on demand with an integrated representational state transfer (REST) API. This returns data for a specific application in CycloneDX SBOM format—a standard designed for use in application security contexts and supply chain component analysis. Additionally, data from the API can be mined and transformed outside of the Veracode Platform.
- Intelligent Remediation: The Continuous Software Security Platform will leverage technology acquired from Jaroona to detect and remediate software vulnerabilities through machine learning. Jaroona, which was recognized by Gartner Research as a “Cool Vendor” in 2021, outperforms traditional approaches by 7x to 10x in terms of accuracy, false negatives, and false positive rates, and reduces the burden on technical resources.
According to Tabrez Naqvi, Director of Information Security and Risk at Cox Automotive, “The security of our products and services is very important to us, and Veracode helps us ensure that we never lose our customers' trust and confidence."
For more information on the Veracode Continuous Software Security Platform visit https://www.veracode.com/platform.
¹Gartner, Inc. ”Predicts 2022: Consolidated Security Platforms Are the Future” by Charlie Winckless, Joerg Fritsch, Peter Firstbrook, Neil MacDonald, Brian Lowans, 1 December 2021
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005671/en/
Contact information
For more information, please contact:
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
